Muna Aylisha Isaac Escorcia

Dr. Muna Aylisha Isaac Escorcia


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeisón Rambal-Torres
Jeisón Rambal-Torres
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.

17 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeison Rambal-Torres
Jeison Rambal-Torres
EOElber Osorio-Rodríguez
Elber Osorio-Rodríguez
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.

Verified
Journal Article
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
JSJuan Solano-Ropero
Juan Solano-Ropero
VOValentina Rada Obeso
Valentina Rada Obeso
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
JSJuan Solano-Ropero
Juan Solano-Ropero
VOValentina Rada Obeso
Valentina Rada Obeso
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.